TRT Bone Density in Men Over 50 What RCTs and 2025 Updates Show

Key takeaways

• TRT increases BMD by roughly 3–7% in hypogonadal men over 50, with larger gains at the lumbar spine than the hip.
• Benefits emerge within 12 months, often build through year two, and can sustain up to three years.
• Fracture reduction with TRT remains unproven; antiresorptives are still first-line for osteoporosis.
• 2025 FDA updates removed the boxed cardiovascular warning but added a blood pressure warning; careful monitoring is essential.
• Best candidates: men with confirmed symptomatic hypogonadism and low BMD—not men with age-related low-normal T alone.

Why TRT bone density matters for men over 50

As men age, declining testosterone and rising osteoporosis risk often collide. Testosterone replacement therapy (TRT) is sometimes discussed for bone health, but what does high-quality evidence actually show? Recent randomized controlled trials (RCTs) and 2025 safety updates offer clearer guidance: TRT can increase bone mineral density (BMD) in hypogonadal men over 50—particularly at the lumbar spine—with gains sustained for up to three years. Whether those improvements translate into fewer fractures remains uncertain.

Bone loss accelerates with age in men, and hypogonadism (low testosterone with symptoms) can compound this decline. Lower testosterone is associated with reduced BMD, changes in body composition (more fat mass, less lean mass), and increased fall risk factors, which together may heighten the chance of fracture over time. Understandably, men ask whether restoring testosterone to physiologic levels can strengthen bones.

The short answer from randomized trials: yes, TRT can improve BMD in men with confirmed hypogonadism. But the clinical endpoint that matters most—fewer fractures—hasn’t been definitively demonstrated.

What the randomized trials show

The most cited modern RCT in older men is the Testosterone Trials (T-Trials), a set of coordinated studies in men aged 65 and older with unequivocally low testosterone (mean baseline around 234 ng/dL). In the Bone Trial component, one year of transdermal TRT increased lumbar spine volumetric BMD by about 7.5% and hip BMD by about 3.3% compared with placebo. Notably, men whose testosterone levels were restored into the mid-normal physiological range (roughly 500–800 ng/dL) experienced the most robust gains.

Across multiple RCTs and meta-analyses synthesized in recent reviews, a consistent pattern emerges:

• Magnitude: BMD increases generally range from about 3% to 7%, most prominently at the lumbar spine, with more modest gains at the hip.
• Population: Benefits are strongest in men with confirmed hypogonadism (typically defined as total testosterone <300 ng/dL plus symptoms), not in men with age-related low-normal levels.
• Time course: Meaningful increases appear within 12 months, with further accrual into the second year.

These improvements in BMD often coincide with favorable shifts in body composition. Recent summaries report average gains in lean mass (around 1.6 kg) and strength with TRT, factors that can affect balance and fall risk. While those are valuable functional outcomes, they still don’t equate to definitive fracture reduction.

How durable are the gains?

Beyond the first year, extension studies and meta-analyses indicate that TRT-related BMD improvements can be sustained for up to three years, with a tendency to plateau. This durability supports the view that TRT helps normalize bone remodeling when testosterone is restored to physiologic levels in appropriately selected men.

What remains less clear is whether gains persist indefinitely or require ongoing therapy to maintain. Most high-quality RCTs have been limited to one to three years. Longer-term comparative data beyond that window are sparse, and existing studies vary by dosing, formulation, and baseline bone health.

Fractures: the key outcome we still don’t have

While BMD is a validated surrogate marker in osteoporosis research, fracture reduction is the clinical endpoint that matters most to patients. To date, fracture outcomes with TRT are inconclusive. The TRAVERSE program—the large cardiovascular safety trial that informed the FDA’s 2025 label changes—also evaluated fractures in a dedicated analysis, but results did not demonstrate a clear fracture risk reduction signal.

This matters practically. For men at high fracture risk or with established osteoporosis, guideline-backed antiresorptive therapy (e.g., bisphosphonates) remains the first-line treatment to prevent fractures. TRT is not a substitute for those agents. Instead, TRT may serve as a complementary therapy for bone health in men who have both hypogonadism and low BMD, provided there is a clear clinical indication, shared decision-making, and ongoing monitoring.

Who might benefit most—and who might not

More likely to benefit:

• Men over 50 with confirmed hypogonadism (typically total testosterone <300 ng/dL on two morning tests) plus compatible symptoms.
• Men with low BMD at baseline, especially at the spine.
• Men whose testosterone levels are restored into the mid-normal physiologic range during therapy.

Less likely to benefit:

• Men with age-related borderline low testosterone but without clear hypogonadism; current labeling maintains a limitation of use for age-related low T alone.
• Men seeking TRT solely for bone benefits without other hypogonadal features or without low testosterone confirmed by testing.

These distinctions matter because RCT benefits on BMD have been most consistent when TRT is used for clear, symptomatic hypogonadism—not as a general anti-aging or bone-boosting intervention.

Safety, monitoring, and the 2025 label update

In February 2025, the FDA updated class-wide testosterone labeling to reflect two key developments:

• Cardiovascular outcomes: The Boxed Warning for major adverse cardiovascular events (MACE) was removed. This change reflects results from the TRAVERSE cardiovascular outcomes trial, which found no increased risk of MACE with TRT (hazard ratio 0.96, 95% CI 0.78–1.17).
• Blood pressure: The FDA added a class-wide blood pressure warning based on ambulatory blood pressure monitoring studies. In practice, this underscores the need to check and manage blood pressure during TRT.

Other safety considerations remain relevant:

• Erythrocytosis: TRT can increase hematocrit, which requires periodic monitoring and management to mitigate thrombotic risk.
• Prostate monitoring: PSA and prostate health assessments are typically part of TRT oversight in older men.
• Formulation differences: Trials include transdermal and injectable preparations, but head-to-head skeletal outcomes are limited; formulation choice should be individualized.
• Indication: TRT remains indicated for men with hypogonadism due to known causes and is not approved solely for age-related declines.

For men considering TRT primarily for bone health, these safety updates do not diminish the BMD benefits shown in RCTs—but they reinforce the need for medical supervision and individualized risk–benefit evaluation.

Practical implications for bone-focused TRT care

• Expectations: In RCTs, BMD increases of 3–7% are typical, with the greatest response at the spine over 12–24 months. Hip gains are smaller but meaningful.
• Monitoring: Clinicians commonly track hematocrit, PSA/prostate health, and blood pressure during TRT. Bone density (via DXA) may be re-evaluated periodically to assess response.
• Comprehensive care: Combine TRT with nutrition that supports bone health, resistance and weight-bearing exercise, fall-prevention strategies, and—when indicated—evidence-based osteoporosis medications. TRT does not replace first-line therapies when fracture risk is high.
• Realistic goals: Consider TRT as a way to help restore physiology and support skeletal remodeling in hypogonadal men, not as a standalone fracture-prevention strategy.

Open questions for 2026 and beyond

• Durability: Do BMD gains persist beyond three years, and what happens after TRT discontinuation?
• Fractures: Can adequately powered, long-term trials clarify whether TRT reduces fractures in high-risk hypogonadal men?
• Subgroups: What is the optimal formulation and target testosterone range for men with obesity, diabetes, or other comorbidities from a bone standpoint?
• Combination therapy: How does TRT interact with antiresorptives or anabolic osteoporosis therapies? Are there additive or synergistic effects on BMD or fracture reduction?

A balanced conclusion

For hypogonadal men over 50, the randomized evidence is consistent: TRT can increase BMD—particularly at the lumbar spine—by roughly 3–7%, with benefits appearing within a year and sustained for up to three years. These effects are most evident when baseline testosterone is clearly low and restored to mid-normal physiological levels during therapy.

At the same time, fracture reduction—the outcome that matters most—remains unproven. 2025 FDA updates endorse cardiovascular risk neutrality in a large outcomes trial but introduce a class-wide blood pressure warning, reinforcing the need for careful monitoring. For men with both hypogonadism and low BMD, TRT can be a helpful component of comprehensive bone health care, but it is not a substitute for first-line osteoporosis therapies when fracture risk is high.

If you’re evaluating TRT for bone health, an evidence-based discussion with your clinician—grounded in confirmed hypogonadism, personal risk factors, and clear goals—remains the best next step.

Disclaimer

This article is for educational purposes only and is not medical advice. Do not start, change, or stop any medication based on this content. Consult a qualified healthcare professional for personalized guidance.

Sources

• Peer‑reviewed review on TRT and bone health (PMC12535424)
• FDA testosterone information for patients and providers
• FDA class‑wide labeling changes for testosterone products (2025)
• The Testosterone Trials: effects in older men, including the Bone Trial (PMC5433755)
• UF Health summary: testosterone treatment, bone density, and anemia